MX350096B - Preservación asistida con vacío de productos biológicos, en particular de vacunas. - Google Patents
Preservación asistida con vacío de productos biológicos, en particular de vacunas.Info
- Publication number
- MX350096B MX350096B MX2014001626A MX2014001626A MX350096B MX 350096 B MX350096 B MX 350096B MX 2014001626 A MX2014001626 A MX 2014001626A MX 2014001626 A MX2014001626 A MX 2014001626A MX 350096 B MX350096 B MX 350096B
- Authority
- MX
- Mexico
- Prior art keywords
- vaccines
- assisted
- preservation
- vacuum
- biological products
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18051—Methods of production or purification of viral material
Abstract
La presente invención se refiere a un proceso para vitrificar material biológico, caracterizado porque comprende las etapas de formular una preparación biológica líquida, someter la preparación a cambios controlados en presión y temperatura para reducir el contenido de humedad dela formulación a menos del 5% en peso, para de esta manera vitrificar el material biológico; en donde el proceso además comprende las etapas de: (a) adicionar a la preparación líquida ingredientes biológicos activos, estabilizadores, que reducen o eliminan el daño inducido al someter los ingredientes biológicos a medios de preservación criogénicos, incluyendo el perlado, vitrificación y deshidratación por congelación, y opcionalmente adicionar uno o más adyuvantes; (b) llenar frasquitos o viales con la preparación biológica de la etapa (a); (c) cargar los frasquitos o viales en el recipiente con temperatura controlada, en donde la temperatura está entre -15°C y 10°C, particularmente entre -10°C y 5°C y aún más particularmente 5°C; (d) reducir la presión de aire del recipiente con temperatura controlada hasta una presión dentro del intervalo de 1.5 KPa-3KPa (15-30 mbars); ( e) mantener la presión obtenida durante la etapa (d) pro entre 5 y 20 minutos, particularmente entre 10 y 15 minutos, para permitir que la temperatura del producto se estabilice y permitir a los gases volátiles, incluyendo carbonatos, que se han liberado de la preparación biológica, en donde la temperatura del recipiente permanece entre 4°C a 6°C, ó 5°C durante ésta etapa; (f) disminuir la presión del aire del recipiente de entre 0.4 KPa a 0.7KPa (4 a 7 mbares), ó 0.5 KPa (5 mbars), durante 5 a 20 minutos; (g) mantener la presión de la etapa (f) durante 30 a 60 minutos, que permite que la preparación biológica llegue a ser más concentrada; (h) incrementar la temperatura del recipiente de temperatura negativa a positiva (entre 30°C a 50°C) durante el curso de entre 45 y 85 minutos, o 60 minutos, y mantener la presión constante hasta que se alcanza entre 10°C a 20°C, o 15°C; (i) reducir la presión del aire del contenedor entre 0.15 KPa a 0.4KPa (1.5 a 4 mbars), ó 0.3 KPa (3 mbars), para acelerar la concentración, y hasta que la temperatura del recipiente alcance y mantenga a 30°C durante entre 30 minutos a 90 minutos, o 60 minutos; (j) reducir adicionalmente la presión a entre 0.05 KPa y 0.4 KPa (0.5 Y 4.0 mbars), o de 0.1 KPa (1mbar), y mantener la presión constante hasta que se haya completado la espumación; (k) reducir adicionalmente presión entre 5x10-4KPa Y 100X 10-4 (5µbar y 100 µbar), o 25x10-4 Kpa (25 µbar), mientras que se mantiene la temperatura en 30°C durante entre 400 a 2400 o más minutos, hasta que se obtiene la humedad deseada de entre 0.5% a 15% , o entre 1% a 4% ; (l) tapar los frasquitos o viales mientras se encuentran en el recipiente de secado por congelación, para de esta manera completar el método de vitrificación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490987P | 2011-08-12 | 2011-08-12 | |
PCT/US2012/040230 WO2013025274A1 (en) | 2011-08-12 | 2012-05-31 | Vacuum -assisted preservation of biological products, in particular of vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014001626A MX2014001626A (es) | 2015-03-09 |
MX350096B true MX350096B (es) | 2017-08-25 |
Family
ID=46246235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001626A MX350096B (es) | 2011-08-12 | 2012-05-31 | Preservación asistida con vacío de productos biológicos, en particular de vacunas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10166188B2 (es) |
EP (1) | EP2741740B1 (es) |
JP (1) | JP6041361B2 (es) |
CN (1) | CN103841963B (es) |
CA (1) | CA2844927C (es) |
DK (1) | DK2741740T3 (es) |
EA (1) | EA031229B1 (es) |
ES (1) | ES2626297T3 (es) |
HU (1) | HUE035774T2 (es) |
LT (1) | LT2741740T (es) |
MX (1) | MX350096B (es) |
SI (1) | SI2741740T1 (es) |
WO (1) | WO2013025274A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015274813B2 (en) | 2014-06-09 | 2019-08-22 | Somnio Global Holdings, Llc | Capillary assisted vitrification processes and devices |
WO2018102586A1 (en) | 2016-11-30 | 2018-06-07 | Merial, Inc. | Attenuated swine influenza vaccines and methods of making and use thereof |
CN107043740A (zh) * | 2017-05-10 | 2017-08-15 | 浙江美保龙生物技术有限公司 | 一种mdbk细胞培养液及其制备方法、使用方法 |
CN107217029A (zh) * | 2017-06-08 | 2017-09-29 | 浙江美保龙生物技术有限公司 | 一种pk‑15细胞培养液及其制备方法、使用方法 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11287185B1 (en) | 2020-09-09 | 2022-03-29 | Stay Fresh Technology, LLC | Freeze drying with constant-pressure and constant-temperature phases |
CN113046412B (zh) * | 2021-03-29 | 2021-12-14 | 深圳市麦瑞科林科技有限公司 | 一种高安全性的非灭活型病毒保存液及制备方法 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3783098A (en) | 1971-08-10 | 1974-01-01 | Cornell Res Foundation Inc | Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same |
US3915794A (en) | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
US4000256A (en) | 1975-04-30 | 1976-12-28 | Merck & Co., Inc. | Varicella vaccine and process for its preparation |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
EP0386185A1 (fr) | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
US5178862A (en) | 1989-12-01 | 1993-01-12 | Parhelion Corporation | Canine distemper virus vaccine and method of preparation |
AT395893B (de) | 1990-01-10 | 1993-03-25 | Mayreder Kraus & Co Ing | Befestigungsvorrichtung zum verbinden von bauteilen |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
CA2051092C (en) * | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5846805A (en) | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
EP0683816B1 (en) | 1993-02-08 | 2000-11-02 | Bayer Corporation | Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US6485729B1 (en) | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
EP0872249A4 (en) | 1995-03-17 | 2001-10-24 | Hisamitsu Pharmaceutical Co | GENE TRANSFER PREPARATION |
CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第xiii因子の安定化された水性液製剤 |
FR2741806B1 (fr) | 1995-11-30 | 1998-02-20 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline |
FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
US5866401A (en) | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
JP2000511059A (ja) * | 1996-05-29 | 2000-08-29 | ユニバーサル プリザーベーション テクノロジーズ,インコーポレイテッド | ガラス化による長期貯蔵保存 |
US6509146B1 (en) * | 1996-05-29 | 2003-01-21 | Universal Preservation Technologies, Inc. | Scalable long-term shelf preservation of sensitive biological solutions and suspensions |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
FR2750866B1 (fr) | 1996-06-27 | 1998-11-27 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751223B1 (fr) | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
ATE198910T1 (de) | 1996-10-17 | 2001-02-15 | Oxford Biomedica Ltd | Retrovirale vektoren |
FR2757061B1 (fr) | 1996-12-16 | 1999-03-26 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
US6051238A (en) | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
US6290967B1 (en) | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
FR2758986B1 (fr) | 1997-01-31 | 1999-04-30 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6368603B1 (en) | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
CA2301328A1 (en) | 1997-08-13 | 1999-02-25 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
EP0913177A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
CA2332150A1 (en) | 1998-05-15 | 1999-11-25 | Rami Skaliter | Mechanical stress induced genes, expression products therefrom, and uses thereof |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
US6017537A (en) | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
US6541001B1 (en) * | 1999-08-24 | 2003-04-01 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
US6872357B1 (en) * | 2000-11-22 | 2005-03-29 | Quadrant Drug Delivery Limited | Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying |
US20030064000A1 (en) * | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
AU2003230955A1 (en) * | 2002-05-01 | 2003-11-17 | Cryoglass Llc | Cryopreservation system for liquid substances |
WO2005058356A2 (en) | 2003-12-17 | 2005-06-30 | Wyeth | Methods for porducing storage stable viruses and immunogenic compositions thereof |
US20060141483A1 (en) | 2004-12-23 | 2006-06-29 | Calton Gary J | Stabilization of viral compositions |
US7956160B2 (en) * | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
GB0517688D0 (en) * | 2005-08-31 | 2005-10-05 | Cambridge Biostability Ltd | Improvements in the stabilisation of biological materials |
RS51996B (en) | 2005-09-16 | 2012-04-30 | Merial Ltd. | Freeze dried vaccine stabilizers |
US20090155351A1 (en) | 2005-10-04 | 2009-06-18 | Alk-Abello A/S | Solid Vaccine Formulation |
BRPI0718548A2 (pt) * | 2006-11-07 | 2013-11-12 | Sanofi Pasteur Biologics Co | Estabilização de vacinas por liofilização |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
CN102686241A (zh) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
US20120222979A1 (en) * | 2011-03-04 | 2012-09-06 | Elwha LLC, a limited liability company of the State of Delaware | Glassy compositions |
WO2020053940A1 (ja) | 2018-09-10 | 2020-03-19 | 株式会社Nttドコモ | ユーザ端末 |
-
2012
- 2012-05-31 EA EA201400216A patent/EA031229B1/ru unknown
- 2012-05-31 LT LTEP12726998.3T patent/LT2741740T/lt unknown
- 2012-05-31 HU HUE12726998A patent/HUE035774T2/en unknown
- 2012-05-31 WO PCT/US2012/040230 patent/WO2013025274A1/en active Application Filing
- 2012-05-31 EP EP12726998.3A patent/EP2741740B1/en active Active
- 2012-05-31 ES ES12726998.3T patent/ES2626297T3/es active Active
- 2012-05-31 US US13/485,437 patent/US10166188B2/en active Active
- 2012-05-31 CA CA2844927A patent/CA2844927C/en active Active
- 2012-05-31 DK DK12726998.3T patent/DK2741740T3/en active
- 2012-05-31 MX MX2014001626A patent/MX350096B/es active IP Right Grant
- 2012-05-31 SI SI201231009T patent/SI2741740T1/sl unknown
- 2012-05-31 CN CN201280046735.7A patent/CN103841963B/zh active Active
- 2012-05-31 JP JP2014525994A patent/JP6041361B2/ja active Active
-
2018
- 2018-11-07 US US16/182,868 patent/US10653627B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE035774T2 (en) | 2018-05-28 |
SI2741740T1 (sl) | 2017-08-31 |
JP2014521742A (ja) | 2014-08-28 |
US10166188B2 (en) | 2019-01-01 |
EA201400216A1 (ru) | 2014-06-30 |
US20190070117A1 (en) | 2019-03-07 |
CN103841963B (zh) | 2018-04-24 |
WO2013025274A1 (en) | 2013-02-21 |
CA2844927C (en) | 2017-10-31 |
EA031229B1 (ru) | 2018-12-28 |
ES2626297T3 (es) | 2017-07-24 |
CA2844927A1 (en) | 2013-02-21 |
CN103841963A (zh) | 2014-06-04 |
US20130040370A1 (en) | 2013-02-14 |
DK2741740T3 (en) | 2017-06-06 |
EP2741740A1 (en) | 2014-06-18 |
LT2741740T (lt) | 2017-08-10 |
MX2014001626A (es) | 2015-03-09 |
EP2741740B1 (en) | 2017-05-03 |
US10653627B2 (en) | 2020-05-19 |
JP6041361B2 (ja) | 2016-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014001626A (es) | Preservacion asistida con vacio de productos biologicos, en particular de vacunas. | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
MY187874A (en) | Antibody formulations | |
MX337397B (es) | Vacunas anti-virales dirigidas a celulas que presentan antigeno. | |
IN2014CN03892A (es) | ||
MX2011009437A (es) | Vacunas contra cancer a base de de celulas presentadoras de antigeno. | |
NZ603863A (en) | Concentration and lyophilization of influenza vaccine antigens | |
MX2011009438A (es) | Anticuerpos anti-cd40 y usos de los mismos. | |
MY170720A (en) | Antibody formulations | |
EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
MX349657B (es) | Composiciones de vacuna de matriz de proteína que incluyen policationes. | |
WO2012145238A3 (en) | Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules | |
MX2014005372A (es) | Molecula portadora que comprende un antigeno spr0096 y un spr2021. | |
MX2016014868A (es) | Metodos para secar por congelacion y rehidratar productos biologicos. | |
WO2014004385A3 (en) | Anti-cancer vaccines | |
NZ725212A (en) | Group a streptococcus vaccine | |
HUE051711T2 (hu) | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül | |
WO2012173819A3 (en) | Anti-cd3 therapies | |
MX368484B (es) | Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. | |
MX2013009529A (es) | Tratamiento de enfermedad de crohn con fistulas. | |
IN2014MN01381A (es) | ||
WO2012149525A3 (en) | Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection | |
DK201370413A (en) | Salmonid alphavirus protein e2 | |
WO2013093514A3 (en) | Vaccines - peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assignment |
Owner name: MERIAL, INC. |
|
FG | Grant or registration |